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Judging a virus by its cover
Eva Szomolanyi-Tsuda and Raymond M. Welsh
Department of Pathology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
The production of protective neutralizing antibodies occurs quickly in 
some viral infections but very slowly in others. In a new study, surface gly-
coproteins (the targets of neutralization) of 2 different viruses were geneti-
cally switched. Analysis of the neutralizing antibody response to each of 
the 2 parent and recombinant viruses in infected mice revealed that the 
speed of neutralizing antibody induction was intrinsically dependent on 
the surface glycoprotein and not the rest of the virus (see the related article 
beginning on page 988).
We are taught not to judge a book by its 
cover, but the “cover” of a virion may be all 
that concerns the immune system when it 
comes to its speed in generating neutraliz-
ing antibodies. Neutralizing antibodies are 
a major component of the immune defense 
mechanism against viral infections. These 
antibodies bind to accessible surface deter-
minants on virions, including attachment 
proteins, and render viruses noninfectious. 
Mechanisms of neutralization include anti-
body interference with the virus binding to 
host cell surface receptors and the blocking 
of viral fusion with the host cell membrane, 
thereby preventing the entry of infectious 
virions (1). Antiviral neutralizing anti-
bodies protect the host from reinfection, 
keep low-grade, persistent infections from 
recrudescing, and prevent infection when 
administered or elicited prophylactically. 
For this reason, the efficient induction of 
high titers of neutralizing antibodies is a 
major goal in vaccine design.
Variations in the timing  
of neutralizing antibody induction
Many viral infections induce neutralizing 
antibody responses rapidly. These respons-
es can be detected as early as days 3–7 of 
infection with rota and vesicular stomati-
tis viruses (VSVs) in mice, rabies and yel-
low fever viruses in humans, and influenza 
and polio viruses in both humans and 
mice (2–5). The generation of neutralizing 
antibodies early during the course of infec-
tion enables them to participate in virus 
clearance; in some infections, such as VSV, 
neutralizing antibodies play major roles in 
the resolution of acute infection and recov-
ery. In other viral infections there is a long 
delay between initial infection and the gen-
eration of high levels of neutralizing anti-
bodies. Such delays may extend from one 
to several months and are often observed 
in infections with hepatitis C virus, hepa-
titis B virus, and HIV in humans, and 
with lymphocytic choriomeningitis virus 
(LCMV) in humans and mice (6–9). In 
this issue of the JCI, Pinschewer and col-
leagues pose the following question: What 
factor(s) determine the timing of the onset 
of efficient neutralizing antibody respons-
es to viral infection (10)? The ability of a 
virus to induce neutralizing antibodies 
early in the course of infection could be 
due either to: (a) an inherent property of 
the viral protein target of neutralization 
antibodies; (b) the organization or topog-
raphy of the virion antigen display, which 
may influence the triggering of the immu-
noglobulin receptor on B cells and the sub-
sequent activation of antibody-secreting B 
cells (11, 12); or (c) the nature of the virus 
infection, including the ability of the virus 
to propagate in antigen-presenting cells, 
induce cytokines, and induce and exhaust 
T cell immune responses that may affect 
the generation of antibody responses.
Swapping viral glycoproteins
Pinschewer et al. (10) used a genetic 
approach to address the question of what 
makes some viruses proficient at the 
rapid induction of high titers of neutral-
izing antibodies. They made recombinant 
viruses of VSV (called recombinant VSV, 
or rVSV), a potent inducer of neutraliz-
ing antibodies, and also of LCMV (called 
recombinant LCMV, or rLCMV), an inef-
ficient inducer of neutralizing antibodies, 
by swapping their surface glycoproteins, 
which are targets of antibody-mediated 
neutralization. This resulted in rLCMV 
expressing VSV-glycoprotein (rLCMV/
VSV-GP) and rVSV expressing LCMV-gly-
coprotein (rVSV/LCMV-GP). The authors 
then compared the neutralizing antibody 
responses to each of the 2 parent and 
recombinant viruses in infected mice. The 
results suggest a simple and at first sur-
prising answer (Figure 1). The responses to 
the recombinant viruses were determined 
exclusively by the surface glycoprotein and 
not by the rest of the virus. rLCMV/VSV-
GP induced rapid and efficient neutraliz-
ing antibody responses (Figure 1D), similar 
to the responses induced by the parental 
VSV strain (Figure 1A); mice infected with 
rVSV/LCMV-GP produced few detectable 
neutralizing antibodies during the 30-day 
observation period (Figure 1C), similarly 
to mice infected with LCMV (Figure 1B). 
Most other parameters of infection with 
parental LCMV and rVSV/LCMV-GP were 
similar or the same, including the induc-
tion of T cell responses, even though the 
quantity of viral antigen and cellular tro-
pism of the recombinants may have been 
influenced by the surface glycoprotein.
Are differences in timing due 
to germ-line immunoglobulin 
sequences?
How then could the intrinsic properties of 
the viral surface glycoprotein account for the 
timing of neutralizing antibody responses? 
In some cases, highly glycosylated proteins, 
such as the HIV or simian immunodefi-
ciency virus (SIV) envelope glycoproteins, 
can only induce low titers of neutralizing 
antibodies. Removal of glycosylation sites of 
the SIV glycoprotein allows the induction of 
antibodies with increased neutralizing activ-
ity (13). The high levels of glycosylation, 
however, may interfere with the ability of 
the virus to induce high titers of neutraliz-
ing antibodies, but do not affect the timing 
of neutralizing antibody production.
The answer to the question posed by 
Pinschewer and colleagues may have more 
to do with how the antibody response 
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evolves. Neutralizing antibodies tend to be 
of high affinity to virion surface proteins 
in order to compete with virion binding to 
host receptors (14). Most antibodies reach 
high affinity as a result of affinity matu-
ration, a CD4+ T cell–dependent process 
that involves somatic hypermutation and 
subsequent selection by antigen-loaded 
follicular dendritic cells in the germinal 
centers. Somatic hypermutation is an 
antigen-dependent reaction that occurs in 
B cells during an immune response and is 
responsible for introducing point muta-
tions into the variable regions of immuno-
globulin genes with a rate 103–104 times 
higher than the spontaneous mutation 
rate of other mammalian genes. While 
many of these mutations are deleterious, 
some cause the antibody to have a higher 
affinity for the antigen. B cells harbor-
ing these higher-affinity antibodies are 
selected to survive preferentially. Whereas 
most antibodies specific for protein anti-
gens start out with low germline affinities 
(105–106/mol), VSV-GP–specific antibod-
ies, remarkably, have quite high affinities 
(108–1010/mol) by day 4 after infection. 
The average affinities of these antibodies 
encoded by unmutated germline sequences 
change very little following day 4 of infec-
tion, although somatic hypermutation 
does occur after days 6–8 in the germinal 
centers (15, 16). The high, germline-encod-
ed affinities enable VSV to elicit protective 
neutralizing IgM antibodies on days 3–4. 
These IgM antibodies are generated in a 
helper T cell–independent fashion (12). 
Hence, this capacity to secrete Ig that is 
reactive with a virus at high affinity at the 
start of the B cell response may explain the 
rapid neutralizing antibody induction in 
response to VSV glycoproteins (10, 12).
A remaining question is whether the 
induction of a high-affinity, germline-
encoded, protective antibody response dur-
ing early infection is a phenomenon unique 
to VSV infection in the mouse. Does this 
response occur during infection of other 
host species with viruses other than LCMV 
and VSV, or does the study of Pinschewer 
et al. (10) merely illustrate a curious excep-
tion? Some of the other viruses known to 
induce early neutralizing antibody respons-
es, such as influenza and polio, induce 
early, protective IgM responses. These 
early IgM responses to influenza virus are 
T cell–independent (17), and influenza 
virus induces protective antibody respons-
es in mice deficient in activation-induced 
deaminase (AID), an enzyme essential for 
both isotype switching and somatic hyper-
mutation (18). In the AID-deficient mice, 
the unmutated IgM must have met the 
affinity requirements necessary for virus 
neutralization and host protection. Influ-
enza virus–specific antibody responses, like 
those to VSV, eventually undergo somatic 
hypermutation (19), but this process is not 
required for their protective or neutraliz-
ing capacity. Detailed studies on antiviral 
neutralizing antibody affinities at different 
stages of infection have not been done in 
other viral systems.
In the event that a viral infection induces 
germline-encoded, high-affinity antibodies 
specific to the viral surface proteins, there 
Figure 1
Kinetics of neutralizing antibody responses 
induced in mice following infection with (A) 
VSV, a bullet-shaped rhabdovirus containing 
one RNA species and (B) LCMV, an arenavirus 
containing 2 virion RNAs and some ribosomes. 
By reverse genetic techniques, the virion sur-
face glycoproteins were swapped between 
the two viruses (C and D), and the rapidity in 
generating neutralizing antibodies was found 
to correlate with the surface glycoprotein 
expressed on the recombinant virus (10).
commentaries
 The Journal of Clinical Investigation   http://www.jci.org   Volume 114   Number 7   October 2004 897
would be no need for T cell help, formation 
of germinal centers, and the time-consum-
ing process of somatic hypermutation and 
selection before the neutralizing antibodies 
are produced. In contrast, the late-forming 
neutralizing antibody responses to viruses 
such as HIV, hepatitis B virus, hepatitis 
C virus, and LCMV, may require affinity 
maturation in order to reach neutraliza-
tion potential. Additional challenges in 
containing these infections may also be 
envisioned as a result of the ability of all of 
these viruses to either replicate within or 
induce clonal exhaustion of T cells, which 
are needed for the affinity maturation pro-
cess described above.
There may not be a quick and simple 
solution for rapidly eliciting neutralizing 
antibody responses to certain viruses if the 
results obtained by Pinschewer et al. (10) 
with the recombinant LCMV and VSV with 
swapped surface glycoproteins reflect a 
general rule. The initial affinity of antibod-
ies to a given viral protein cannot be altered 
by placing the epitope into a new, highly 
immunogenic carrier. Fortunately, most 
immunization strategies allow sufficient 
time for neutralizing antibodies to develop 
prior to exposure to the infectious virus, 
independent of whether the viral antigens 
are characterized as potent or inefficient 
inducers of neutralizing antibodies.
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